Impact of Surveillance Imaging in Patients With HPV-Associated Oropharyngeal Carcinoma Treated With Definitive Radiation and Chemotherapy
- 25 September 2024
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 48 (1) , 28-33
Abstract
Objectives: Surveillance imaging for HPV-associated oropharyngeal carcinomas (OPCs) differs among physicians and institutions. Surveillance imaging can detect disease progression earlier, but can also contribute to anxiety and cost, without proven survival benefits. We sought to determine practice patterns of surveillance imaging and the number of surveillance scans needed to detect one recurrence in patients with HPV-associated OPCs. Methods: We performed a retrospective cohort study between 2017 and 2019 (median follow-up: 39.9 mo) of consecutive patients with locally advanced HPV-associated OPC who received definitive concurrent chemoradiotherapy (CRT) with 70 Gy at a single institution. Patients were followed post-CRT and their surveillance scans were recorded. Recurrences were classified as detected by first post-treatment scans, surveillance scans, clinical exams, or incidental findings. The number of surveillance scans needed to detect 1 recurrence was determined by dividing the number of surveillance scans by the number of recurrences detected by surveillance scans. Results: Among 276 patients with a median follow-up of 39.9 months, there were 28 recurrences. Of all recurrences, 11 (39.3%) were detected by the first post-treatment scan, 11 (39.3%) by surveillance scan, 5 (17.9%) by clinical exam, and 1 (3.6%) was incidentally found. A total of 694 surveillance scans were taken. The number of surveillance scans needed to detect 1 recurrence was 64 overall, 45 within 2 years, and 248 beyond 2 years from treatment. Conclusions: First post-treatment scans and surveillance scans detected more recurrences than clinical exams. A high burden of surveillance scans is needed to detect 1 recurrence, especially beyond 2 years from treatment.Keywords
This publication has 17 references indexed in Scilit:
- Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus–Associated Oropharyngeal Carcinoma Treated With Definitive ChemoradiotherapyJAMA Oncology, 2022
- Costs Associated With Imaging Surveillance After Treatment for Head and Neck CancerJAMA Otolaryngology–Head & Neck Surgery, 2021
- Head and neck imaging surveillance strategy for HPV-positive oropharyngeal carcinoma following definitive (chemo)radiotherapyRadiotherapy and Oncology, 2021
- Association of NCCN-Recommended Posttreatment Surveillance With Outcomes in Patients With HPV-Associated Oropharyngeal Squamous Cell CarcinomaJAMA Otolaryngology–Head & Neck Surgery, 2019
- Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapyCancer, 2019
- Posttreatment surveillance PET/CT for HPV‐associated oropharyngeal cancerHead & Neck, 2018
- Determining optimal follow‐up in the management of human papillomavirus‐positive oropharyngeal cancerCancer, 2015
- PET‐CT and the detection of the asymptomatic recurrence or second primary lesions in the treated head and neck cancer patientThe Laryngoscope, 2013
- Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrenceCancer, 2012
- Postradiotherapy surveillance practice for head and neck squamous cell carcinoma—too much for too little?Head & Neck, 2003